Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials.

ABSTRACT:

Background

It is unclear whether the time-varying mediation effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the three-point major adverse cardiovascular event (3P-MACE) outcomes, including nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death, via HbA_1c, urine albumin-to-creatinine ratio (UACR), and systolic blood pressure (SBP) vary by types of GLP-1RAs, and patient subgroups.

Methods

A causal mediation analysis was applied to assess the mediation effects of HbA_1c, UACR, and SBP on the 3P-MACE with liraglutide and semaglutide over time, using the LEADER and SUSTAIN-6 trials. We further explored the heterogeneity in mediation effects in subsets of vulnerable patients, including those with an estimated glomerular fi

SUBMITTER: Peng ZY 

PROVIDER: S-EPMC12751512 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature